top of page
Completed

NCT02336815 : Phase 2 - Selinexor Treatment of Refractory Myeloma (STORM)

Updated: Jun 21, 2022

STORM

Selinexor Treatment of Refractory Myeloma (STORM)

STORM trial SELINEXOR

This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd) dosed twice weekly in four-week cycles, in patients with penta-refractory MM (Parts 1 and 2) or quad refractory MM (Part 1 only).


Sponsor:

Karyopharm Therapeutics Inc


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT02336815

Official Title: A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab

First Posted : January 13, 2015


Click here for details on ClinicalTrials.gov

 

 

Drug: Selinexor

Drug: Dexamethasone

 

PMID: 31433920

N Engl J Med; Aug 2019


PMID: 29381435

J Clin Oncol; March 2018

 

Locations

United States, Alabama

United States, Arizona

United States, California

United States, Connecticut

United States, Florida

United States, Georgia

United States, Hawaii

United States, Illinois

United States, Indiana

United States, Iowa

United States, Kentucky

United States, Maryland

United States, Massachusetts

United States, Michigan

United States, Minnesota

United States, Missouri

United States, New Jersey

United States, New York

United States, North Carolina

United States, Ohio

United States, Oregon

United States, Pennsylvania

United States, Tennessee

United States, Texas

United States, Washington

Europe

Austria

Belgium

France

Germany

Greece

Posts Archive
bottom of page